Skip to main content
ANTX
NASDAQ Life Sciences

AN2 Therapeutics Q2 Loss Widens to $8.2M on Higher R&D; Cash Runway into 2029

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$5.87
Mkt Cap
$211.415M
52W Low
$1
52W High
$6.91
52W Position info
487% above low
Off High info
15% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ANTX has more than doubled off its 52-week low of $1 on light trading volume (0.2× avg).

Summary

AN2 Therapeutics reported a Q2 net loss of $8.19 million, or $0.18 per share, widening from the prior year on increased R&D spending tied to advancing three Phase 2 programs. The company ended the quarter with $79.9 million in cash, which it expects to fund operations into 2029. Pipeline catalysts include a Phase 2 chronic Chagas disease trial starting late 2026, enrollment in a global Phase 2 polycythemia vera trial in Q4 2026, and a second boron-based candidate by year-end. The loss and spending ramp are in line with a pre-revenue biotech scaling clinical activity, but the cash position provides a long runway to reach key data readouts.

At the time of this announcement, ANTX was trading at $5.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $211.4M. The 52-week trading range was $1.00 to $6.91. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

ANTX - Latest Insights

ANTX
Nov 09, 2026, 7:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $5.27 info
Change: +$1.27 (+32%) info
Market Cap: $196.548M info
ANTX
Nov 02, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $4.54
Real-time Price: $5.27 info
Change: +$0.730 (+16%) info
Market Cap: $196.548M info
ANTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.87
Real-time Price: $5.27 info
Change: -$0.600 (-10%) info
Market Cap: $196.548M info
ANTX
Aug 11, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $5.27 info
Change: -$0.600 (-10%) info
Market Cap: $196.548M info
ANTX
Jun 04, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.17
Real-time Price: $5.27 info
Change: +$1.10 (+26%) info
Market Cap: $196.548M info